Shield Therapeutics Looking At US Options For Feraccru
Executive Summary
The UK biotech has revised its business strategy over the past year, and Shield's CEO believes the company's lead product for iron deficiency is now well positioned to compete with current and potential entrants in the therapeutic sector.
You may also be interested in...
Bouncing Back From A Phase III Flop
The passing of a decade always brings with it an inevitable glance in the rear-view mirror to see how far we have come. The pharma industry is no different and it would be remiss to ignore the failings of the industry’s collective R&D engine while also celebrating its successes.
Keeping Track: Turalio, Nubeqa And Accrufer Mark Trio Of Novel Drug Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
AZ/FibroGen's Roxadustat Superior To Epoetin-Alfa In Chronic Renal Disease With Anemia
Positive top-line Phase III data from five studies, including the finding of superior efficacy to epotin-alfa, puts roxadustat in the driving seat as a new class of anemia agents heads toward the marketplace, but cardiovascular safety needs confirming.